AR030172A1 - Composicion en polvo que comprende una cantidad efectiva de un antagonista de histamina h2 y tableta que la comprende - Google Patents
Composicion en polvo que comprende una cantidad efectiva de un antagonista de histamina h2 y tableta que la comprendeInfo
- Publication number
- AR030172A1 AR030172A1 ARP000106431A ARP000106431A AR030172A1 AR 030172 A1 AR030172 A1 AR 030172A1 AR P000106431 A ARP000106431 A AR P000106431A AR P000106431 A ARP000106431 A AR P000106431A AR 030172 A1 AR030172 A1 AR 030172A1
- Authority
- AR
- Argentina
- Prior art keywords
- acidulant
- effective amount
- hydroxyl groups
- powder composition
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 239000000843 powder Substances 0.000 title abstract 2
- 239000000739 antihistaminic agent Substances 0.000 title 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 abstract 2
- 239000003485 histamine H2 receptor antagonist Substances 0.000 abstract 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 1
- 239000001361 adipic acid Substances 0.000 abstract 1
- 235000011037 adipic acid Nutrition 0.000 abstract 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 abstract 1
- 239000001569 carbon dioxide Substances 0.000 abstract 1
- 229910002092 carbon dioxide Inorganic materials 0.000 abstract 1
- 229960001380 cimetidine Drugs 0.000 abstract 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 abstract 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960001596 famotidine Drugs 0.000 abstract 1
- 239000001530 fumaric acid Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 229960004872 nizatidine Drugs 0.000 abstract 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 abstract 1
- 229960000620 ranitidine Drugs 0.000 abstract 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 229940014800 succinic anhydride Drugs 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composicion en polvo que comprende una cantidad efectiva de un antagonista de histamina H2, un acidulante, y un, material alcalino que reaccionará con el acidulante en presencia de agua para formar dioxido de carbono de tal forma que dicha composicion está sustancialmente libre de acidulante que contiene grupos hidroxilo y el acidulante es un acidulante que contiene sustancialmente grupos no hidroxilo, solido bajo condiciones ambiente. Preferentemente, el acidulante que contiene grupos no hidroxilo es seleccionado del grupo integrado por ácido adípico, ácido succínico, ácido fumárico, anhídrido succínico y mezclas de los mismos. Por su parte, el antagonista de histamina H2 es preferentemente seleccionado del grupo integrado por ranitidina, cimetidina, nizatidina, famotidina y sales farmacéuticamente aceptables de los mismos. Tabletas que comprende la composicion de acuerdo con lo anteriormente descripto, juntamente con un lubricante.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/455,233 US6264984B1 (en) | 1999-12-06 | 1999-12-06 | Effervescent histamine H2 antagonist composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR030172A1 true AR030172A1 (es) | 2003-08-13 |
Family
ID=23807966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000106431A AR030172A1 (es) | 1999-12-06 | 2000-12-05 | Composicion en polvo que comprende una cantidad efectiva de un antagonista de histamina h2 y tableta que la comprende |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6264984B1 (es) |
| EP (1) | EP1237543B1 (es) |
| JP (1) | JP2003515553A (es) |
| KR (1) | KR100795259B1 (es) |
| CN (1) | CN1211077C (es) |
| AR (1) | AR030172A1 (es) |
| AT (1) | ATE309783T1 (es) |
| AU (1) | AU1766101A (es) |
| BR (1) | BR0015779A (es) |
| CA (1) | CA2394902C (es) |
| CY (1) | CY1105495T1 (es) |
| DE (1) | DE60024132T2 (es) |
| DK (1) | DK1237543T3 (es) |
| ES (1) | ES2252078T3 (es) |
| MX (1) | MXPA02005534A (es) |
| PE (1) | PE20010909A1 (es) |
| WO (1) | WO2001039750A1 (es) |
| ZA (1) | ZA200203168B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070154542A1 (en) * | 2005-12-30 | 2007-07-05 | Cogentus Pharmaceuticals, Inc. | Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors |
| US9717726B2 (en) * | 2013-03-14 | 2017-08-01 | Maregade Rx, LLC | Product and method for treating diarrhea |
| WO2015157729A1 (en) * | 2014-04-11 | 2015-10-15 | Wilmink Michael | Pharmaceutical formulations an comprising analgesic agent, a nonsteroidal anti-inflammatory agent, a gastric acid production suppressant and an anti-nauseant |
| CN105997922A (zh) * | 2016-06-12 | 2016-10-12 | 佛山市腾瑞医药科技有限公司 | 一种盐酸雷尼替丁泡腾片及其制备方法 |
| EP3558296B1 (en) | 2016-12-23 | 2023-06-28 | Maregade RX, LLC | Low dose product and method for treating diarrhea |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2593065B1 (fr) | 1986-01-22 | 1988-09-09 | Smith Kline French Lab | Couples effervescents, compositions effervescentes d'antagonistes h2 de l'histamine les contenant et leur preparation. |
| FR2633181B1 (fr) | 1988-06-24 | 1992-01-10 | Glaxo Lab Sa | Composition pharmaceutique a base de ranitidine et son procede de preparation |
| DE4027927A1 (de) * | 1990-09-04 | 1992-03-05 | Bayer Ag | Brausekomponente und verfahren zu ihrer herstellung |
| CA2061520C (en) | 1991-03-27 | 2003-04-22 | Lawrence J. Daher | Delivery system for enhanced onset and increased potency |
| US5503846A (en) * | 1993-03-17 | 1996-04-02 | Cima Labs, Inc. | Base coated acid particles and effervescent formulation incorporating same |
| ES2126147T3 (es) | 1993-09-09 | 1999-03-16 | Gerhard Gergely | Granulado efervescente y procedimiento para su preparacion. |
| WO1995010274A1 (en) | 1993-10-14 | 1995-04-20 | F.H. Faulding & Co. Limited | Aqueous pharmaceutical composition |
| IL112779A (en) | 1994-03-01 | 1999-11-30 | Gergely Gerhard | Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation |
| ES2136157T3 (es) | 1994-03-01 | 1999-11-16 | Gerhard Gergely | Producto granular o comprimido que contiene un sistema efervescente y una sustancia farmaceutica activa, asi como un procedimiento para su preparacion. |
| US5824339A (en) | 1995-09-08 | 1998-10-20 | Takeda Chemical Industries, Ltd | Effervescent composition and its production |
| US5728401A (en) * | 1997-04-16 | 1998-03-17 | Ranbaxy Laboratories, Ltd. | Effervescent ranitidine formulations |
-
1999
- 1999-12-06 US US09/455,233 patent/US6264984B1/en not_active Expired - Lifetime
-
2000
- 2000-11-16 BR BR0015779-1A patent/BR0015779A/pt not_active Application Discontinuation
- 2000-11-16 WO PCT/US2000/031360 patent/WO2001039750A1/en active IP Right Grant
- 2000-11-16 MX MXPA02005534A patent/MXPA02005534A/es active IP Right Grant
- 2000-11-16 ES ES00980395T patent/ES2252078T3/es not_active Expired - Lifetime
- 2000-11-16 CN CNB008167729A patent/CN1211077C/zh not_active Expired - Fee Related
- 2000-11-16 CA CA002394902A patent/CA2394902C/en not_active Expired - Lifetime
- 2000-11-16 KR KR1020027007193A patent/KR100795259B1/ko not_active IP Right Cessation
- 2000-11-16 DK DK00980395T patent/DK1237543T3/da active
- 2000-11-16 EP EP00980395A patent/EP1237543B1/en not_active Expired - Lifetime
- 2000-11-16 JP JP2001541483A patent/JP2003515553A/ja active Pending
- 2000-11-16 AU AU17661/01A patent/AU1766101A/en not_active Abandoned
- 2000-11-16 AT AT00980395T patent/ATE309783T1/de active
- 2000-11-16 DE DE60024132T patent/DE60024132T2/de not_active Expired - Lifetime
- 2000-12-05 AR ARP000106431A patent/AR030172A1/es unknown
- 2000-12-06 PE PE2000001304A patent/PE20010909A1/es not_active Application Discontinuation
-
2002
- 2002-04-22 ZA ZA200203168A patent/ZA200203168B/xx unknown
-
2006
- 2006-01-27 CY CY20061100116T patent/CY1105495T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA02005534A (es) | 2002-11-29 |
| WO2001039750A1 (en) | 2001-06-07 |
| DE60024132T2 (de) | 2006-08-03 |
| DE60024132D1 (de) | 2005-12-22 |
| EP1237543B1 (en) | 2005-11-16 |
| BR0015779A (pt) | 2002-07-09 |
| AU1766101A (en) | 2001-06-12 |
| EP1237543A1 (en) | 2002-09-11 |
| US6264984B1 (en) | 2001-07-24 |
| KR20020070309A (ko) | 2002-09-05 |
| CA2394902A1 (en) | 2001-06-07 |
| CY1105495T1 (el) | 2010-04-28 |
| DK1237543T3 (da) | 2006-01-16 |
| ZA200203168B (en) | 2003-09-23 |
| CN1211077C (zh) | 2005-07-20 |
| JP2003515553A (ja) | 2003-05-07 |
| CN1407885A (zh) | 2003-04-02 |
| CA2394902C (en) | 2006-08-08 |
| ATE309783T1 (de) | 2005-12-15 |
| PE20010909A1 (es) | 2001-11-11 |
| ES2252078T3 (es) | 2006-05-16 |
| KR100795259B1 (ko) | 2008-01-15 |
| EP1237543A4 (en) | 2004-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG104843A (en) | Solid, quick dissolving cetirizine formulations | |
| ES2091878T3 (es) | Composicion plaguicida. | |
| UA66847C2 (uk) | Тверда швидкорозчинна композиція селегіліну та спосіб її одержання | |
| AR022065A1 (es) | Tabletas masticables suaves | |
| ES468140A1 (es) | Procedimiento para la obtencion de geles polimeros estables. | |
| WO2002045573A3 (en) | Condom with male genital desensitizer lubricant | |
| BR0007648A (pt) | Sistema de propaganda por correio eletrônico, terminal de correio eletrônico, e, dispositivo de retransmissão | |
| ES2128471T3 (es) | Agente administrable oralmente que disminuye el colesterol. | |
| AR030172A1 (es) | Composicion en polvo que comprende una cantidad efectiva de un antagonista de histamina h2 y tableta que la comprende | |
| LV11984A (lv) | Farmaceitiska kompozicija putojosa dzeriena pagatavosanai | |
| CO5160322A1 (es) | Composiciones antiperspirantes | |
| RU2001126719A (ru) | Дигетерозамещенные ингибиторы металлопротеазы | |
| DK1104289T3 (da) | Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister | |
| WO2005007137A8 (de) | Ambroxolhaltige tabletten | |
| TW348063B (en) | A pharmaceutical composition in the form of plaster containing pranoprofen | |
| WO1996019189A3 (en) | Dental hygiene compositions | |
| DE3773440D1 (de) | Pharmazeutische zusammensetzungen fuer suppositorien. | |
| MXPA05003283A (es) | Composicion de polimero y formas de dosis que comprenden la misma. | |
| BR0014213A (pt) | Caramelos duros com estabilidade aperfeiçoada ao armazenamento | |
| KR890006235A (ko) | 피페리디노알칸올용 제약 조성물 | |
| BRPI0212195B8 (pt) | composições contendo pectina e ácido ascórbico | |
| MX9707695A (es) | Empaque que contiene una formulacion de solucion acuosa de clorhidrato de procaterol, y una formulacion de solucion acuosa de clorhidrato de procaterol. | |
| FR2673842B1 (fr) | Nouvelles compositions liquides a base de derives de la piperidine substitues en 1,4. | |
| UY29106A1 (es) | Composición farmacéutica sólida soluble formada por una composición farmacéutica activa y una composición eutéctica hidrosoluble y procedimiento de preparacion | |
| ES2127305T3 (es) | Una forma farmaceutica para la administracion rectal de compuestos farmacologicamente activos. |